Effect of empagliflozin on copeptin levels in patients with recent acute coronary syndrome and newly detected dysglycaemia: a post-hoc analysis of the SOCOGAMI randomized controlled trial

Cardiovasc Diabetol. 2026 Jul 28;25(1):212. doi: 10.1186/s12933-026-03312-y.ABSTRACTBACKGROUND: Copeptin, a surrogate marker for vasopressin secretion, is associated with cardiovascular disease, insulin resistance and dysglycaemia. The cardioprotective effects of sodium-glucose cotransporter 2 inhib

E Elena Fortin

Nuclear class 3 PI3K co-activates fasting-specific chromatin remodelling

Nat Cell Biol. 2026 Jul 28. doi: 10.1038/s41556-026-02030-7. Online ahead of print.ABSTRACTTranscriptional remodelling during fasting ensures metabolic adaptation and provides health benefits across species. Although several regulators of fasting-induced transcription and chromatin are known, how nu

N Nathaniel F Henneman

Investigating Novel Inflammatory Biomarkers and Pathways in Cardiac Cachexia

Heart Lung Circ. 2026 Jul 28:S1443-9506(26)00215-5. doi: 10.1016/j.hlc.2026.03.064. Online ahead of print.ABSTRACTBACKGROUND: Cardiac cachexia (CC) is an indicator of advanced heart failure (AHF), with significant unintentional weight loss (UWL) and poor prognosis. Its diagnostic criteria incorporat

M Mansimran Singh Dulay

Sodium-glucose cotransporter 2 inhibitors in diabetic kidney disease

Kidney Res Clin Pract. 2026 Jul 28. doi: 10.23876/j.krcp.26.139. Online ahead of print.ABSTRACTDiabetic kidney disease (DKD) is a major contributor to chronic kidney disease (CKD) and end-stage kidney disease worldwide, and is strongly associated with increased cardiovascular morbidity and mortality

D Da Woon Kim